Bayer funds research and development at Oncogene:
This article was originally published in Clinica
Executive Summary
Bayer's US diagnostics group has agreed to fund research and development into cancer diagnostics at Oncogene Science. The funding will help develop Oncogene's existing clinical and research products and will also finance a joint development programme for new cancer markers. The deal gives Oncogene, which is based in Uniondale, New Jersey, access to the market through the world's fifth largest diagnostics businesses. (see Clinica No 708, pp 10-11).
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.